



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88152

Zhiwen ZHOU, et al.

Appln. No.: 10/539,446

Group Art Unit: 1614

Confirmation No.: 8654

Examiner: Unassigned

Filed: June 20, 2005

For:

A SET OF OLIGO-NUCLEOTIDES AGAINST HIV INFECTION AND ITS APPLICATION IN THE

PREVENTION AND TREATMENT OF ACQUIRED IMMUNE DEFICIENCY SYNDROME

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN:

Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the

following correction:

ASSIGNEE: BEIJING JOINN PHARMACEUTICAL CENTER

Verification for the requested correction is indicated on the PTO-Form 1595 and Assignment filed June 20, 2005.

Respectfully submitted,

Registration No. 41,239

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 7, 2006 \



23373

United States Patent and Trademark Office

AUG 0 7 2006

TES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS

P.O. Box 1450
Alexandra, Virginia 22313-1450
www.uspto.gov

 APPL NO.
 FILING OR 371 (c) DATE
 ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET NO
 DRAWINGS
 TOT CLMS
 IND CLMS

 10/539,446
 06/20/2005
 1614
 900
 6
 8
 1

CONFIRMATION NO. 8654

FILING RECEIPT

OC00000019327146

SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037

Date Mailed: 06/20/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Zhiwen Zhou, Beijing, CHINA; Yuxia Feng, Beijing, CHINA; Conglin Zuo, Beijing, CHINA; Yuejuan Li, Beijing, CHINA;

ASSIGNEE: Beijing Joinn Pharmaceutical Center

Power of Attorney: The patent practitioners associated with Customer Number 23373.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/CN03/01068 12/16/2003

Foreign Applications

CHINA 02156785.9 12/18/2002

Projected Publication Date: 09/28/2006

Non-Publication Request: No

Early Publication Request: No

Title

Group of nucleic acid fragments for prevention of hiv infection or aids and the usage thereof

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

۲٬۰ ر * matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Assignment

Whereas, We, Zhiwen ZHOU, Yuxia FENG, Conglin ZUO, and Yuejuan LI, all of c/o Beijing Joinn Pharmaceutical Center, No. 9 Haiyinglu, ZhongGuanCuen Fengtai Kejiyuan, Fentai District, Beijing 100070, China, hereinafter called assignors, have invented certain improvements in

DEFI	A SET OF OLIGO-NUCLEOTIDES AGA LICATION IN THE PREVENTION AND TO ICIENCY SYNDROME and executed an appos of America therefor on	REATMENT OF ACQUIRED IMMUNE lication for Letters Patent of the United
acqui	Whereas, BEIJING JOINN PHARMACE gGuanCuen Fengtai Kejiyuan, Fentai District, let the entire right, title, and interest in the application of the property of the property of the spatents to be obtained therefor;	Beijing 100070, China, (assignee), desires to
	Now therefore, for valuable consideration, re	eceipt whereof is hereby acknowledged,
inventunder issue succes neces	We, the above named assignors, hereby sell, nee, its successors and assigns, the entire right, tion disclosed therein for the United States of A 35 U.S.C. §119, and we request the Director of any Letters Patent granted upon the invention seroes and assigns; and we will execute without sary by the assignee in connection with the United the States of A 25 and 35 and 35 and 36 and	title and interest in the application and the America, including the right to claim priority of the U.S. Patent and Trademark Office to set forth in the application to the assignee, its further consideration all papers deemed
(Appl	We hereby authorize and request our attorney ylvania Avenue, NW, Washington, DC 20037-ication number and Confirm plication number and filing date of said application	3213 to insert here in parentheses ation number, filed)
Date:	Jun. 15, 2005,	Zhiven Zhou.
Date:	s/Zhiwen ZHOU Jun, 15, 2005	Yuxia FENCE
	Jun. 15. 2005	Zuo cong-Lin
	s/Conglin ZUO	Y . / 1
Jale:	Jun, 15, 2005 s/Yuejuan Ll	Tuejuan L1



MODIFIED Form PTO-1595 RECORDATION	N FORM COVER SHEET U.S. DEPARTMENT OF COMMERCE		
(Rev. 10/02) PATE	ENTS ONLY U.S. Patent and Trademark Offic		
To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof			
1. Name of conveying party(ies):	2. Name and address of receiving party(ies):		
Zhiwen ZHOU	BEIJING JOINN PHARMACEUTICAL CENTER		
Yuxia FENG Conglin ZUO	No. 9 Haiyinglu, ZhongGuanCuen		
Yuejuan LI	Fengtai Kejiyuan, Fentai District,		
- 3- 3-3	Beijing 10070, P.R. China		
Additional name(s) of conveying party(ies) attached? Yes No			
3. Nature of conveyance:			
☑ Assignment ☐ Merger			
☐ Security Agreement ☐ Change of Name			
Other			
Execution Date: June 15, 2005	Additional court () 8 - 11 - () - 1 - 10 - 17 - 17 - 17 - 17 - 17 - 17		
4. Application number(s) or patent number(s):	Additional name(s) & address(es) attached? Yes No		
If this document is being filed together with a new application, the execution date of the application is: June 15, 2005			
A. Patent Application No.(s)	B. Patent No.(s)		
Unknown	Unknown		
Additional numbers attached?			
5. Name and address of party to whom correspondence	6. Total number of applications and patents involved:		
concerning document should be mailed:	1		
SUGHRUE MION, PLLC	7. Total fee (37 CFR 3.41): \$40.00		
WASHINGTON OFFICE	☑ Enclosed.		
23373	☐ Authorized to be charged to Deposit Account No. 19-4880.		
CUSTOMER NUMBER	The USPTO is directed and authorized to charge all required		
Í	fees, except for the Issue Fee and the Publication Fee, to Deposit		
·	Account No. 19-4880. Please also credit any overpayments to said Deposit Account.		
Ì	8. Deposit Account Number:		
	19-4880		
DO NOT I	(Attach duplicate copy of this page if paying by deposit account)		
9. Statement and signature.			
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.			
- Survey DR	June 20, 2005		
Susan Perng/Pan Reg. No.	41,239 Date		
Total number of pages including cover sheet, attachments, and documents: 2			
Mail documents to be recorded with required cover sheet information to:			
MAIL STOP ASSIGNMENT RECORDATION SERVICES			
Director of the U.S. Patent and Trademark Office			
P.O. Box 1450			
Alexandria, VA 22313-1450			